APRG1 Inhibitors are a distinct class of chemical compounds designed to specifically target and inhibit the activity of the APRG1 protein, a member of a broader protein family that is implicated in various cellular processes, including gene regulation, protein interactions, and potentially signal transduction. The exact biological functions of APRG1 are still under exploration, but it is understood that this protein plays a role in maintaining cellular homeostasis and may be involved in the regulation of transcriptional activity or protein complex formation. APRG1 Inhibitors function by binding to specific regions of the APRG1 protein, such as its active site, DNA-binding domains, or regions crucial for protein-protein interactions. This binding interferes with the normal function of APRG1, either by blocking its interaction with other cellular components, inhibiting its ability to bind DNA, or preventing it from participating in essential molecular processes.
The effectiveness of APRG1 Inhibitors is highly dependent on their chemical structure and molecular properties. These inhibitors are typically designed to mimic the natural ligands, substrates, or interacting partners of APRG1, allowing them to compete for binding sites and effectively block the protein's activity. The molecular design of these inhibitors often includes hydrophobic regions that interact with the non-polar surfaces of APRG1, enhancing their binding affinity. Additionally, polar or charged groups may be incorporated to form hydrogen bonds or electrostatic interactions with key amino acids in the protein's functional domains. The inhibitors are also optimized for solubility, stability, and bioavailability, ensuring that they can effectively reach and inhibit APRG1 in the cellular environment. The kinetics of binding, including the rates of association and dissociation between the inhibitor and APRG1, are critical factors that determine the potency and duration of inhibition. By studying the interactions between APRG1 Inhibitors and their target protein, researchers can gain valuable insights into the molecular mechanisms underlying APRG1's role in cellular processes and the broader implications of modulating its activity. This understanding is crucial for elucidating the complex pathways in which APRG1 is involved and how its inhibition can impact cellular functions and overall biological systems.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By increasing acetylation of histones, it can change the expression of genes, potentially leading to downregulation of C3orf35 by altering chromatin accessibility. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor. It can cause hypomethylation of DNA, which could affect the promoter region of C3orf35, potentially reducing its expression. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 also inhibits DNA methyltransferases, potentially leading to demethylation of the C3orf35 gene promoter and a decrease in its expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds to GC-rich DNA sequences, which could interfere with transcription factor binding at the C3orf35 promoter and reduce its expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine can alter DNA and RNA synthesis, which might nonspecifically reduce the expression levels of various genes, including C3orf35. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA, inhibiting RNA polymerase and thereby reducing RNA synthesis. This action could decrease C3orf35 mRNA levels. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin is a potent inhibitor of RNA polymerase II, which could lead to a reduction in the transcription of mRNA, including that of C3orf35. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus inhibits mTOR, which is involved in the regulation of protein synthesis and could indirectly reduce the expression of many genes, potentially including C3orf35. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide has been shown to inhibit the transcription of various genes, which could include C3orf35, although the precise mechanism is not fully understood. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine is another DNA methyltransferase inhibitor that could lead to gene expression changes, potentially reducing C3orf35 expression through demethylation of gene regulatory regions. | ||||||